<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>贝壳社 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-14T20:16:02+08:00</updated>
  <subtitle>贝壳社是国内领先的医疗健康创新创业服务平台，集聚政府、上市公司、投资机构和三甲医院等产业高端资源，提供一站式的全球生命健康人才项目引进、转化孵化和产业化等全产业链协同创新和赋能服务。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>辉瑞基因治疗领域全布局：六年，30亿美元合作与收购</title>
    <updated>2020-12-14T17:20:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/J2jix3ncTfC_VORDIqlanw</id>
    <link href="https://mp.weixin.qq.com/s/J2jix3ncTfC_VORDIqlanw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>两款重磅1类新药今日获批：来自恒瑞、海思科</title>
    <updated>2020-12-14T17:20:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/J4BzDQ1TEyKIqeMkWN7h-w</id>
    <link href="https://mp.weixin.qq.com/s/J4BzDQ1TEyKIqeMkWN7h-w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>​微脉再获1亿美元融资，百度资本领投</title>
    <updated>2020-12-14T17:20:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/fc-eXZodWik0Ve8M0T1-UQ</id>
    <link href="https://mp.weixin.qq.com/s/fc-eXZodWik0Ve8M0T1-UQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球首批！诺华siRNA疗法获欧盟上市批准；医保谈判即将开始 | 贝壳日报</title>
    <updated>2020-12-14T17:20:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/QFL5IJODDT0C85Knp47pwg</id>
    <link href="https://mp.weixin.qq.com/s/QFL5IJODDT0C85Knp47pwg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>多发性骨髓瘤中国市场潜力达300亿元，多款创新药物布局蓝海市场</title>
    <updated>2020-12-11T17:46:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/FbHnR-JE6pJQXE6pQn72Lg</id>
    <link href="https://mp.weixin.qq.com/s/FbHnR-JE6pJQXE6pQn72Lg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>三部门发文，“互联网+”医疗迎来新拐点！</title>
    <updated>2020-12-11T17:23:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/JMAFtPGxHNJxkiTNZaWJqQ</id>
    <link href="https://mp.weixin.qq.com/s/JMAFtPGxHNJxkiTNZaWJqQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>最新！外媒评选“2020年度生物技术公司”，ADC药物明星公司Seagen当选</title>
    <updated>2020-12-11T17:23:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/24yVhB-UhIwv4pfJv4aMDA</id>
    <link href="https://mp.weixin.qq.com/s/24yVhB-UhIwv4pfJv4aMDA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>吉利德计划约14.5亿欧元收购MYR，囊获新型肝炎疗法；艾伯维JAK抑制剂连续取得进展，治疗特异性皮炎达到3期终点 | 贝壳日报</title>
    <updated>2020-12-11T17:23:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/MJGijeRXKXj9Ky2R2akgCQ</id>
    <link href="https://mp.weixin.qq.com/s/MJGijeRXKXj9Ky2R2akgCQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>刚刚，和铂医药港交所上市破发，这也许是好事</title>
    <updated>2020-12-10T10:54:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/oKOrL-3kPWwMHVT8xrmQAA</id>
    <link href="https://mp.weixin.qq.com/s/oKOrL-3kPWwMHVT8xrmQAA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>​辉瑞肺炎球菌疫苗获FDA优先审评资格，防护20种血清型；​治疗溃疡性结肠炎，艾伯维JAK抑制剂达到3期临床终点 | 贝壳日报</title>
    <updated>2020-12-10T10:54:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/kuskvBeFB-8zr2gzFz3i4g</id>
    <link href="https://mp.weixin.qq.com/s/kuskvBeFB-8zr2gzFz3i4g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>盘点 | 2020年FDA首次批准上市的27种新药</title>
    <updated>2020-12-09T18:02:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/g7s909SLvfPvsilhysukVA</id>
    <link href="https://mp.weixin.qq.com/s/g7s909SLvfPvsilhysukVA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>华大智造科创板IPO获受理：招股书披露的这几点值得关注</title>
    <updated>2020-12-09T18:02:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/3geuhgUmlhzY71Eb_7Y3-g</id>
    <link href="https://mp.weixin.qq.com/s/3geuhgUmlhzY71Eb_7Y3-g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第四批国采开始报量，44产品、90品规，附产品名单</title>
    <updated>2020-12-09T18:02:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/QiBJ7L9QGIYcUPZ34RSdJw</id>
    <link href="https://mp.weixin.qq.com/s/QiBJ7L9QGIYcUPZ34RSdJw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>安进KRAS抑制剂获FDA突破性疗法认定，年底前递交新药申请；又有一批药废标 | 贝壳日报</title>
    <updated>2020-12-09T18:02:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/3vDgTsqTEr_-57XlmxaCzg</id>
    <link href="https://mp.weixin.qq.com/s/3vDgTsqTEr_-57XlmxaCzg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年10大最舍得研发投入的医疗器械公司，美敦力，强生，西门子…</title>
    <updated>2020-12-08T17:32:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/pbdpj_3RWdWqxmucv_nTXQ</id>
    <link href="https://mp.weixin.qq.com/s/pbdpj_3RWdWqxmucv_nTXQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>君圣泰完成数千万美元B+轮融资，加速推进原创新药多个适应症临床II/III期的全球开发，及新适应症和新品种的临床研究</title>
    <updated>2020-12-08T17:32:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/kn5se1QRTlyeVdSPoYskyw</id>
    <link href="https://mp.weixin.qq.com/s/kn5se1QRTlyeVdSPoYskyw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>索元生物宣布完成近3亿人民币D轮融资​</title>
    <updated>2020-12-08T17:32:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/veVNHIBJixl6cEe_37Xu1Q</id>
    <link href="https://mp.weixin.qq.com/s/veVNHIBJixl6cEe_37Xu1Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>葛兰素史克贝利尤单抗新适应症获批，首款儿童红斑狼疮创新疗法；​德琪医药核心产品全球多中心2/3期临床试验获受理 | 贝壳日报</title>
    <updated>2020-12-08T17:32:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/4R849ylXwVrZptRhUl6TFA</id>
    <link href="https://mp.weixin.qq.com/s/4R849ylXwVrZptRhUl6TFA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医保谈判展望：外企、国内企业，以及潜在受益者</title>
    <updated>2020-12-07T17:30:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/o67-5FijIRnqOIoJqof7lg</id>
    <link href="https://mp.weixin.qq.com/s/o67-5FijIRnqOIoJqof7lg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球首个针对HAE的单克隆抗体（mAb）药物达泽优®（拉那利尤单抗注射液）批准进入中国</title>
    <updated>2020-12-07T17:30:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/T5bMsEj1qaYKPY0lp9k6lA</id>
    <link href="https://mp.weixin.qq.com/s/T5bMsEj1qaYKPY0lp9k6lA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>